Accuray (ARAY) Peer Comparison
$0.27
$0.01
(4.50%)
As on 28-Aug-2026 16:00EDT
Market cap
$33 Mln
Revenue (TTM)
$402 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Edit
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
33 | 12,753 | 10,906 | 9,948 | 9,762 |
Revenue ($ Mln) |
402 | 1,505 | 613 | 785 | 2,589 |
Net Profit ($ Mln) |
-49.19 | 160.59 | -188.05 | 41.54 | 222.40 |
Net Margin (%) |
-12.24 | 10.67 | -30.68 | 5.29 | 8.59 |
RoE (%) |
-80.08 | 10.86 | -28.10 | 1.97 | 3.04 |
Price to Earnings |
-- | 79.35 | -- | 251.81 | 44.47 |
Price-To-Book |
0.75 | 8.41 | 16.38 | 4.86 | 1.26 |
Income Statement ($ Mln)
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
401.95 | -- | -- | -- | -- |
|
Cost of Revenue
|
290.49 | -- | -- | -- | -- |
|
Gross Profit
|
111.45 | -- | -- | -- | -- |
|
Operating Expenses
|
137.90 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-26.44 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-47.25 | -- | -- | -- | -- |
|
Provision for Tax
|
1.95 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-49.19 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
41.70 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
210.57 | -- | -- | -- | -- |
|
Current Liabilities
|
191.41 | -- | -- | -- | -- |
|
Total Liabilities
|
443.68 | -- | -- | -- | -- |
Assets ($ Mln)
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
156.18 | -- | -- | -- | -- |
|
Current Assets
|
287.50 | -- | -- | -- | -- |
|
Total Assets
|
443.68 | -- | -- | -- | -- |
|
Total Debt*
|
183.87 | -- | -- | -- | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.98 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-12.28 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
6.98 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-20.37 | -- | -- | -- | -- |
|
ROE (%)
|
-80.08 | -- | -- | -- | -- |
|
ROA (%)
|
-10.77 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-12.24 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.12 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-2,992.02 | -- | -- | -- | -- |
|
EPS Growth (%)
|
-26.45 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.64 | -- | -- | -- | -- |
|
Price / Book Value
|
0.76 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-12.15 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
4.41 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.23 | -- | -- | -- | -- |
|
Current Ratio
|
1.50 | -- | -- | -- | -- |
|
Quick Ratio
|
0.73 | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -- | -- | -- | -- |
Operating Efficiency Ratios
| Accuray (ARAY) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.77 | -- | -- | -- | -- |
|
Asset Turnover
|
0.88 | -- | -- | -- | -- |
|
Receivable days
|
75.09 | -- | -- | -- | -- |
|
Inventory Days
|
181.12 | -- | -- | -- | -- |
|
Payable days
|
46.89 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
209.32 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
